Navigation Links
New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform
Date:10/5/2007

ressive breast cancer cells. In contrast, no animals immunized with untreated irradiated breast cancer cells survived the subsequent lethal challenge.

"We are encouraged by the results of this study in a very challenging model of breast cancer that further support the broad potential of our anti-PS targeting platform," said Dr. Thorpe. "In view of these results, we are eager to learn more about the anti-cancer utility of these immunocytokine fusion proteins in combination with vaccines and as direct therapeutic agents."

The results of this study also suggest that anti-PS antibodies may be stimulating the immune system by a second mechanism. Phosphatidylserine that has become exposed on the external surface of cells has been shown to dampen the body's natural immune response. Researchers have demonstrated that anti-PS antibodies can block this immune-suppressing signal by binding to and neutralizing the exposed phosphatidylserine, allowing the immune system to mount a more vigorous response.

"This data further supports the broad potential of our anti-PS platform, building on earlier data demonstrating that anti-PS antibodies have the ability to recognize tumors and then initiate a robust immune response," said Steven W. King, president and CEO of Peregrine. "Previously we reported that our fusion proteins demonstrated excellent anti-tumor activity in a number of cancer models as a therapeutic agent. This new research shows that these same agents also have the potential to enhance cancer vaccines, priming the body's immune system to prevent the development of cancer in animals challenged with a normally lethal dose of cancer cells by enhancing the immune response to the tumor."

The new class of immunocytokine fusion protein agents is part of Peregrine's Vascular Targeting Agent (VTA) technology platform for cancer therapy that includes over 200 patents and patent applications covering broad concepts of tumor therapy using agents that target tum
'/>"/>

SOURCE Peregrine Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented
2. Simple, Sensitive, and Rapid Detection of FLAG -Tagged Fusion Proteins
3. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
4. Efficient Cleavage of Fusion Proteins to Yield Native Amino Termini
5. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
6. Principles and applications of electrical cell fusion
7. Principles and applications of electrical cell fusion
8. Production of Hybridomas by Electrofusion
9. Monitoring fluorescence resonance energy transfer (FRET) between GFP fusions in lysates of the yeast Saccharomyces cerevisiae using the Varian Cary Eclipse
10. Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Neogen Corporation (Nasdaq: ... into a strategic agreement with Merck Animal Health to ... The Igenity Dairy Heifer Program consists of ... on the genetic potential of replacement dairy heifers. The ... is born, and is an excellent tool in the ...
(Date:9/18/2014)... 18, 2014 SeqLL Inc., the ... technology, announced today the closing of a $1M ... by Genomic Diagnostic Technologies, will increase the power ... , Founded in March 2013 by Daniel Jones, ... at Helicos BioSciences, SeqLL has continued to offer ...
(Date:9/18/2014)... touch in the course of a day - ... rely on the chemical industry to turn raw ... products into valuable chemicals that are the ingredients ... Sarina Sarina, who achieved outstanding progress in driving ... temperature using light instead of fossil fuels, has ...
(Date:9/18/2014)... York, NY (PRWEB) September 18, 2014 ... completed negotiations with Salem Realty Group and has acquired ... development space within the Salem Executive Complex adjacent to ... ceremony was held on Friday September 5th. Whitehouse Labs ... refit the entire space specifically for package testing. The ...
Breaking Biology Technology:Merck Animal Health to market Neogen's dairy genomic program 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Using solar energy to turn raw materials into ingredients for every day life 2Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4
... Sept. 14 Savient Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated ... chronic gout in adult patients refractory to conventional therapy. ... in patients who have failed to normalize serum uric ...
... SUNNYVALE, Calif., Sept. 14 Molecular Devices, Inc., ... analysis, today announced the launch of two new ... microplate readers, enabling the company to meet all ... future. (Logo:   http://photos.prnewswire.com/prnh/20100406/SF82092LOGO ) ...
... 2011 Fiscal Year Guidance -- HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Biology Technology:FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 2FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 3FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 4FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 5FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 6FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 7FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 8Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs 2Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 2Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 4Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 5Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 6Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 7Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 8
(Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... devastated algal forests in the eastern Mediterranean Sea pose ... their distribution continues to expand as the climate warms, ... team of researchers led by Dr Adriana Vergs of ... Institute for Advanced Studies in Spain, is published in ... team surveyed more than 1000 kilometres of coastline in ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2
... time of the Babylonians to the Incas, terracing has ... hilly croplands. Designing terrace layouts can be time consuming ... developing a Web-based program that will design multiple farm ... help farm experts choose the most efficient and cost-effective ...
... think of Earth as a nurturing place, straining mightily to maintain ... Gaia hypothesis, named for the ancient Greek goddess of Earth, even ... of giant organism, with its complex systems finely tuned to compensate ... is the Gaia view that is out of kilter, says Peter ...
... National Institutes of Health is launching the first ... for rare and neglected diseases. The $24 million ... for Rare and Neglected Diseases Program, or TRND. ... spring, is unusual because TRND creates a drug ...
Cached Biology News:Web-based program designs more efficient farm terrace layouts 2New book suggests Earth perhaps not such a benevolent mother after all 2New book suggests Earth perhaps not such a benevolent mother after all 3NIH announces new program to develop therapeutics for rare and neglected diseases 2NIH announces new program to develop therapeutics for rare and neglected diseases 3NIH announces new program to develop therapeutics for rare and neglected diseases 4NIH announces new program to develop therapeutics for rare and neglected diseases 5
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
Goat polyclonal to Centaurin alpha 2**...
... immobilization can be coupled with a ligand such ... create an affinity matrix of choice. Affi-Gel 10 ... amines. Affi-Gel 10 gel couples neutral or basic ... 15 gel couples acidic proteins with pI less ...
Biology Products: